Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Bionomics Limited participated in the H.C Wainwright BioConnect Conference 2022-01-12 19:00
Bionomics Limited Announces Pricing of Initial Public Offering in the United States 2021-12-16 19:00
U.S. FDA Grants Bionomics Fast Track Designation to BNC210 for the Acute Treatment of Social Anxiety Disorder and Other Anxiety Related Disorders 2021-12-01 19:00
Bionomics Files Registration Statement for Proposed Initial Public Offering in the United States 2021-11-23 19:37
Bionomics Receives FDA Clearance of IND for Evaluation of BNC210 in a Phase 2 Social Anxiety Disorder PREVAIL Study 2021-11-01 18:00
Bionomics Prepares BNC210 for Start of Phase 2 Acute Treatment of Social Anxiety Disorder Trial 2021-09-20 18:00
Bionomics Announces Plans to Conduct U.S. Initial Public Offering 2021-08-02 18:00
Bionomics Initiates Phase 2b ATTUNE Study of BNC210 in PTSD 2021-07-06 18:00
Bionomics BNC210 Expansion into Social Anxiety Disorder 2021-05-10 18:00
Bionomics Successfully Completes A$22.9 million Equity Raise 2021-04-09 18:00
Positive BNC210 7-Day Dosing Pharmacokinetic Study Exceeds Blood Exposure Projected for Phase 2b PTSD Trial 2021-02-22 19:00
Joint feasibility assessment of Bionomics' BNC210 and EmpathBio's MDMA derivative EMP-01 treatment regimen for PTSD 2021-02-17 19:00
$16 Million Capital Raise to Progress Bionomics BNC210 PTSD Trial 2021-02-10 19:00
New investors Thiel and Novogratz introduced to Bionomics by Apeiron Investment Group as part of successful second placement capital raising 2020-09-03 16:34
Commencement of BNC210 Phase 2 Clinical Trial for the Treatment of Agitation 2018-05-24 21:00
1